Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2003
10/23/2003CA2481387A1 Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
10/23/2003CA2481385A1 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
10/23/2003CA2481239A1 Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2
10/23/2003CA2481087A1 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
10/23/2003CA2480882A1 Low-dose potassium supplementation for the prevention and treatment of hypertension
10/23/2003CA2480832A1 Nitric oxide donors, compositions and methods of use
10/23/2003CA2480814A1 Method for inhibiting bone resorption with an alendronate and vitamin d formulation
10/23/2003CA2480775A1 Immunostimulatory g,u-containing oligoribonucleotides
10/23/2003CA2480763A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
10/23/2003CA2480758A1 Tyrosine kinase inhibitors
10/23/2003CA2480754A1 Tyrosine kinase inhibitors
10/23/2003CA2480745A1 Methods for treating tweak-related conditions
10/23/2003CA2480365A1 Iron dextrin compounds for the treatment of iron deficiency anaemia
10/23/2003CA2480213A1 Use of interleukin-19 to treat ovarian cancer
10/23/2003CA2480176A1 Use of interleukin-24 to treat ovarian cancer
10/23/2003CA2479835A1 An ephrin-b receptor protein involved in carcinoma
10/23/2003CA2479714A1 Branched polyamine steroid derivatives
10/23/2003CA2479519A1 Use of interleukin-19 to treat cervical cancer
10/23/2003CA2478392A1 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures
10/23/2003CA2470016A1 Antibiotic product, use and formulation thereof
10/23/2003CA2469736A1 Diphenhydramine tannate solid dose compositions and methods of use
10/23/2003CA2453256A1 Diphenhydramine tannate compositions and methods of use
10/22/2003EP1355159A1 Use of fragments of carbamyl phosphate synthetase I (CPS 1) for the diagnosis of inflammatory diseases and sepsis
10/22/2003EP1355158A1 Method for diagnosing inflammatory and infectious diseases by detecting the phosphoprotein LASP-1 as inflammation marker
10/22/2003EP1355152A1 Compositions for diagnosis and therapy of diseases associated with aberrant expression of kremen
10/22/2003EP1354962A1 Use of the slug gene or of the transcription or expression products thereof in the detection and/or treatment of cancerous cells
10/22/2003EP1354961A1 Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
10/22/2003EP1354953A1 Smac-peptides as therapeutics against cancer and autoimmune diseases
10/22/2003EP1354891A1 Medicament comprising NK4 gene or recombinant NK4 protein
10/22/2003EP1354604A1 Combinations for cardiovascular indications
10/22/2003EP1354603A1 Concomitant drugs
10/22/2003EP1354602A1 Medicinal compositions containing diuretic and insulin resistance-improving agent
10/22/2003EP1354599A2 Pharmaceutical or food composition for treating pathologies related to graft versus host
10/22/2003EP1354581A1 Porous substance and process for producing the same
10/22/2003EP1354580A1 Agents for inhibiting or restoring skin damage caused by drying and method of evaluating the same
10/22/2003EP1354196A2 Diagnostics, drug screening and treatment for cancer
10/22/2003EP1354048A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
10/22/2003EP1354047A2 Methods for screening compounds that modulate lipid metabolism
10/22/2003EP1354039A2 Atp-binding cassette transporter-like molecules and uses thereof
10/22/2003EP1354033A2 Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
10/22/2003EP1354032A2 Gene regulation therapy involving ferritin
10/22/2003EP1353952A2 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
10/22/2003EP1353946A2 Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
10/22/2003EP1353932A1 Compositions containing a ruthenium(iii) complex and a heterocycle
10/22/2003EP1353927A2 Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
10/22/2003EP1353919A2 Novel quinuclidine derivatives and medicinal compositions containing the same
10/22/2003EP1353916A2 Pyrazole compounds useful as protein kinase inhibitors
10/22/2003EP1353727A2 Combinations of an angiotensin receptor antagonist and an anti-hypertensive drugor a statin, for the treatment of sexual dysfunction
10/22/2003EP1353726A2 Rehydration composition
10/22/2003EP1353699A1 Cyclodextrin-drospirenone inclusion complexes
10/22/2003EP1353697A1 Method of preparing biological materials and preparation produced using same
10/22/2003EP1353696A2 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
10/22/2003EP1353695A2 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
10/22/2003EP1353694A2 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
10/22/2003EP1353693A2 Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
10/22/2003EP1353692A2 Methods and compositions for treatment of ocular neovascularization and neural injury
10/22/2003EP1353687A2 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof
10/22/2003EP1353675A2 New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
10/22/2003EP1353669A1 Method for treating glaucoma ib
10/22/2003EP1353665A1 Treatment of depression
10/22/2003EP1353661A2 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes
10/22/2003EP1353659A1 Use of neurotoxic substances in producing a medicament for treating joint pains
10/22/2003EP1353624A2 Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
10/22/2003EP1144423B1 Bis-terpyridine-platinum(ii) complexes
10/22/2003EP1043977B1 Oral pharmaceutical pulsed release dosage form
10/22/2003CN1451014A Peptidomimetic protease inhibitors
10/22/2003CN1451008A Pyranoindoles for treating alaucoma
10/22/2003CN1450923A Method and compositions for administering taxanes orally to human patients
10/22/2003CN1450914A Preparation of aqueous clear solution dosage forms with bile acids
10/22/2003CN1450913A Combination use of bisphosphonates, estrogenic agents and optionally estrogens
10/22/2003CN1450912A CD40 antagonists for use in treating psoriasis and other inflammatory skin conditions
10/22/2003CN1450910A Mutant simplex virus for treating hyperproliferative cell growth
10/22/2003CN1450902A Medicinal composition composed of metformin and glyburide
10/22/2003CN1450898A Compounds for treating fibromyalgia and chronic fatigue syndrome
10/22/2003CN1450896A Use of indole derivatives for intracular pressure for reducing
10/22/2003CN1450893A Method for treatment of sepsis
10/22/2003CN1450883A Transdermal delivery system for alkaloids of aconitum species
10/22/2003CN1450882A Transdermal administration of huperzine
10/22/2003CN1449819A Weishengli oral liquid medicine and preparation process thereof
10/22/2003CN1449742A Insoluble medicine transdemal absorption preparation and process for preparing same
10/22/2003CN1125082C Human chemokine beta-8 chemokine beta-1 and macrophage inflammatory protein-4
10/22/2003CN1124848C Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
10/22/2003CA2382810A1 Composition of traditional chinese medicines for preventing and treating cerebrovascular disease
10/21/2003US6635748 Protein for use as antitumor agent; for use as antimetastsis agent
10/21/2003US6635744 Substantially pure fibroblast growth factor homologous factor-4 polypeptide having specified amino acid sequence; diagnosis and treatment of neurodegenerative and neoplastic disorders
10/21/2003US6635743 Isolated antibody or portion that binds to protein selected from those having specified amino acid sequences or fragments; control apoptosis for treatment of autoimmune disease, graft versus host disease, rheumatoid arthritis and lymphadenopathy
10/21/2003US6635678 Topical application of phenylephrine
10/21/2003US6635677 Potentiating toxicity of 1,3-bis(chloroethyl)2-nitrosourea
10/21/2003US6635676 Non-toxic antimicrobial compositions and methods of use
10/21/2003US6635671 Compounds which affect mRNA stability and uses therefor
10/21/2003US6635651 Inhibitors of thrombin induced platelet aggregation
10/21/2003US6635648 Combination therapy using sympathetic nervous system antagonists and endothelin antagonists
10/21/2003US6635642 Poly(ADP-ribose) polymerase inhibitors; tissue damage treatment
10/21/2003US6635627 Anti-cancer products for treating cystic fibrosis
10/21/2003US6635625 Chondroitin sulfate, quercetin, chitin D-glucosamine sulfate, crown sodium hyaluronate, rutin, olive kernel extract, lecithan, beeswax and water
10/21/2003US6635619 Amino acid sequence 88, 96, 97, 98, 99 or 100; increasing serum and tissue levels of active component
10/21/2003US6635461 Encoded by isolated nucleic acid; has glycosyltransferase activity; given amino acid sequence; useful as diagnostic and therapeutic agent for cancer and thymus-related disorders
10/21/2003US6635431 Recombinant lipolysis stimulated (LSR) comprising polypeptide of given sequence; use for selecting a compound for enhancing lipoprotein uptake in cells expressing the polypeptide
10/21/2003US6635279 Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production
10/21/2003US6635273 Methods of treating vascular diseases characterized by nitric oxide insufficiency
1 ... 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 ... 1151